AbbVie Inc.
ABBVNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026Score 10/3089% above fair value
$288.84−6.05 (-2.05%)
Close on Nov 2, 2026Market cap $510.41BP/E 81.6Yield 2.30%
AbbVie GAAP Effective Tax Rate: 15.5% in Q2 2026, down 23.9 pts from a year earlier.
Latest, Q2 2026
15.5%
Period ended Jun 30, 2026
Change on a year earlier
-23.9 pts
39.4% in Q2 2025
History
24 quarters
Since Q3 2020
Sources
24
Documents cited below
Where the Q2 2026 figure comes from
“|| As reported (GAAP) | $ | 4,278 | $ | 662 | 15.5 | %”
Source: Form 8-K (abbv-20260630xexhibit991.htm, filed 2026-07-31) ↗
Reported in Form 8-K Non-GAAP Reconciliations & Form 10-K Note 14.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
Cite this data
StockData. (2026). AbbVie GAAP Effective Tax Rate (%), quarterly Q3 2020–Q2 2026 [Data set]. Compiled from AbbVie SEC filings and investor materials. https://stockdatahq.com/stocks/abbv/kpis/nongaap-gaap-tax-rate
See every metric in the AbbVie KPI table. Data updated Oct 26, 2026.